CoChat

Harnessing glucagon‐like peptide‐1 receptor agonists for the pharmacological treatment of overweight and obesity

Open access
Burcelin, R., Gourdy, P. · 2017 · Obesity Reviews
Cited by 94

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Summary: Over the past 30 years, there has been a dramatic rise in global obesity prevalence, resulting in significant economic and social consequences. Attempts to develop pharmacological agents to treat obesity have met with many obstacles including the lack of long‐term effectiveness and the potential for adverse effects. Historically, there have been limited treatment options for overweight and obesity; however, since 2012, a number of new drugs have become available. A number of peptides produced in the gut act as key mediators of the gut–brain axis, which is involved in appetite regulation. This review discusses the role of the gut–brain axis in appetite regulation with special focus on glucagon‐like peptide‐1. Liraglutide 3.0 mg, a glucagon‐like peptide‐1 receptor agonist that targets this pathway, is now approved for the treatment of obesity and overweight (body mass index ≥27 kg/m 2) with comorbidities such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. In addition, other glucagon‐like peptide‐1 receptor agonists offer promise for obesity management in the future. This review examines how glucagon‐like peptide‐1 receptor agonists promote weight loss and summarizes the clinical data on weight loss with glucagon‐like peptide‐1 receptor agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/obr.12465

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. 10.1016/S0140-6736(14)60460-8 · DOI · Paper page
  2. Keum N, 2015, Adult weight gain and adiposity‐related cancers: a dose–response meta‐analysis of prospective observational studies, J Natl Cancer Inst, 107, 10.1093/jnci/djv088 · DOI · Paper page
  3. Apovian CM, 2013, The clinical and economic consequences of obesity, Am J Manag Care, 19, s219
  4. 10.2165/00019053-199400051-00007 · DOI · Paper page
  5. 10.1016/j.jacc.2013.11.004 · DOI · Paper page
  6. 10.1038/clpt.2013.204 · DOI · Paper page
  7. 10.1074/jbc.O114.556068 · DOI · Paper page
  8. 10.1155/2012/824305 · DOI · Paper page
  9. 10.1586/17446651.3.5.577 · DOI
  10. 10.1016/j.coph.2007.09.011 · DOI
  11. 10.1177/2040622313506730 · DOI · Paper page
  12. 10.1152/ajpendo.00450.2006 · DOI · Paper page
  13. 10.1900/RDS.2011.8.355 · DOI · Paper page
  14. 10.1152/physrev.00034.2006 · DOI · Paper page
  15. 10.1530/EJE-13-0264 · DOI · Paper page
  16. 10.1017/S0007114513002286 · DOI
  17. 10.2337/diabetes.50.3.609 · DOI · Paper page
  18. 10.1046/j.1471-4159.1996.67051982.x · DOI · Paper page
  19. 10.1152/ajpregu.1999.276.5.R1541 · DOI · Paper page
  20. 10.3945/ajcn.112.047563 · DOI · Paper page
  21. 10.1111/j.1365-2036.2011.04609.x · DOI · Paper page
  22. 10.2337/db14-1514 · DOI · Paper page
  23. Lean M, 2015, The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise program, Endocr Pract, 21, 118, 10.1016/S1530-891X(20)42675-8 · DOI
  24. 10.1016/j.neuroimage.2006.12.035 · DOI
  25. 10.1172/JCI72434 · DOI · Paper page
  26. 10.2337/dc11-0931 · DOI · Paper page
  27. 10.1038/oby.2011.337 · DOI · Paper page
  28. 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  29. 10.2337/dc09-1203 · DOI · Paper page
  30. 10.2337/dc09-0366 · DOI · Paper page
  31. 10.1111/dom.12305 · DOI · Paper page
  32. 10.1002/oby.20042 · DOI · Paper page
  33. 10.2337/dc08-1961 · DOI · Paper page
  34. Blackman A, 2014, Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE sleep apnoea trial, Diabetologia, 57, S85
  35. Saxenda® (Liraglutide 6 mg/ml), 2015, Summary of Product Characteristics
  36. 10.1177/0091270010367653 · DOI

Cited by

See all 94

Metadata

Authors
Burcelin, R., & Gourdy, P.
Venue
Obesity Reviews
Publisher
Wiley
Published
2016-09-16
Volume
18
Issue
1
Pages
86-98
ISSN
  • 1467-7881 (ISSN-L)
  • 1467-789X
OpenAlex
W2521423720
Cited by
94
References
37
FWCI
5.45
Type
journal article
Language
en
Open access
hybrid
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.